TY - JOUR T1 - MHRA drug safety update: hydrochlorothiazide and non-melanoma skin cancer JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 70 LP - 70 DO - 10.1136/dtb.2019.000023 VL - 57 IS - 5 A2 - , Y1 - 2019/05/01 UR - http://dtb.bmj.com/content/57/5/70.abstract N2 - Review of: Medicines and Healthcare products Regulatory Agency. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. Drug Safety Update 2018; 12(4): 2.Key learning pointsThe Medicines and Healthcare products Regulatory Agency has reported a cumulative, dose-dependent risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) in people taking hydrochlorothiazide.It was estimated that around 9 in 100 SCC cases, 11 in 100 SCC lip cancer cases and fewer than 1 in 100 BCC cases diagnosed during the study periods may be attributed to hydrochlorothiazide use.Patients taking hydrochlorothiazide-containing products should be informed of the risk of non-melanoma skin cancer and should regularly check for, and report, any new or changed skin lesions or moles.1 The Medicines and Healthcare products … ER -